Muscle-growth signalling
IGF-1 activates pathways involved in cell growth and protein synthesis.
Explore the research →IGF-1 & GROWTH-SIGNALLING RESEARCH
IGF-1 LR3
A laboratory IGF-1 analogue explored around growth signalling, muscle biology and tissue repair, with direct human evidence still very limited.
IGF-1 signallingCell growthMuscle biology
Primarily a laboratory research compoundIGF-1 biology is well established, but IGF-1 LR3 itself does not have a comparable body of controlled human therapeutic evidence.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in IGF-1 LR3?
IGF-1 LR3 attracts attention because IGF-1 is one of the body's major growth signals. That immediately connects the compound with muscle, recovery and tissue growth — but the LR3 analogue is a research tool, and those popular goals run well ahead of direct human evidence.
Tissue growth & repair
IGF signalling participates in growth and repair across many tissues.
Explore the research →Glucose handling
IGF-1 can influence glucose metabolism and insulin-like signalling.
Explore the research →Longer biological activity
LR3 was engineered to behave differently from native IGF-1 in experimental systems.
Explore the research →THE SCIENCE BIT
Changing how a growth-factor signal is handled.
IGF-1 LR3 is an engineered IGF-1 analogue. Its modifications reduce binding to some IGF-binding proteins, changing its availability in experimental systems.
It can activate the IGF-1 receptor, a growth-signalling receptor. That is different from stimulating the pituitary to release GH, and direct human evidence for LR3 itself is very limited.
See the studies & trials →- IGF-1 receptor
- Growth-factor signalling
- Binding proteins
- Modified interactions
- LR3 analogue
- Distinct from native IGF-1
How this connects to the research
Mostly laboratory evidence; native IGF-1 clinical data do not automatically apply to LR3.
FROM MOLECULE TO TISSUE
Where IGF-1 LR3 connects with the body
These are the tissues and biological systems behind the interest in IGF-1 LR3.
- Muscle cells
- Experimental growth signalling.
- Other tissues
- Cell growth and metabolism.
- Glucose pathways
- Metabolic receptor effects.
The research behind the interest
Muscle-growth signalling
IGF-1 activates pathways involved in cell growth and protein synthesis.
The underlying pathway is real; direct evidence that LR3 safely improves muscle or performance in people is not established.
Strong biology · weak direct human evidenceExplore the studies →Tissue growth & repair
IGF signalling participates in growth and repair across many tissues.
Growth signalling is not automatically beneficial and can have effects outside the intended tissue.
Mechanistic rationaleExplore the studies →Glucose handling
IGF-1 can influence glucose metabolism and insulin-like signalling.
This also creates potential hypoglycaemia and metabolic concerns rather than a simple performance advantage.
Established IGF biologyExplore the studies →Longer biological activity
LR3 was engineered to behave differently from native IGF-1 in experimental systems.
That design is useful in research but does not establish a safe human protocol.
Preclinical / laboratory evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableIGF-1 LR3 in experimental growth-factor research
Cell and animal models
LR3 is used to study IGF-receptor signalling and growth responses.
These experiments do not establish a human performance treatment.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
Direct controlled human evidence for LR3 is extremely limited or absent.
✓
Clinical efficacyEarly
1/5 evidence depth
No established clinical efficacy indication for LR3 was identified.
◇
Safety evidenceEarly
1/5 evidence depth
A consumer safety profile and validated therapeutic dosing framework are lacking.
⌁
Preclinical evidenceStrong
4/5 evidence depth
IGF signalling and LR3 activity are extensively used in experimental research.
HOW TO READ THESE SCORESStrong preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
IGF-1 LR3 research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01IGF-1 signalling
RESEARCH AREA 02Cell growth
RESEARCH AREA 03Muscle biology
RESEARCH AREA 04Metabolism
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with IGF-1 LR3
Online interest focuses heavily on muscle growth, recovery and body composition, while direct human LR3 evidence remains very limited.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Muscle size and training progress
Interest centres on muscle growth and perceived responsiveness to resistance training. Its growth-signalling mechanism is attractive, but modified IGF-1 LR3 is not the same as a validated bodybuilding treatment.
- What makes a report informative
- Strength and body measurements with the complete training history.
- What can muddy the picture
- Other hormones, nutrition and fluid shifts can account for apparent gains.
Recovery from demanding sessions
People hope to tolerate harder training or recover more quickly. A useful account describes the workload and functional change rather than attributing every improvement to growth-factor signalling.
- What makes a report informative
- Recovery and repeat-session performance.
- What can muddy the picture
- More food, better sleep and altered training volume can produce similar effects.
A leaner, fuller appearance
Some interest concerns recomposition or visible muscle fullness. Appearance alone cannot establish new muscle tissue, and feeling unwell from low glucose is not a performance benefit.
- What makes a report informative
- Strength and body-composition measurements rather than fullness alone.
- What can muddy the picture
- The altered binding properties mean native IGF-1 evidence cannot simply be transferred.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Muscle-growth signalling
The underlying pathway is real; direct evidence that LR3 safely improves muscle or performance in people is not established.
Evidence context: Strong biology · weak direct human evidence
Tissue growth & repair
Growth signalling is not automatically beneficial and can have effects outside the intended tissue.
Evidence context: Mechanistic rationale
Glucose handling
This also creates potential hypoglycaemia and metabolic concerns rather than a simple performance advantage.
Evidence context: Established IGF biology
Longer biological activity
That design is useful in research but does not establish a safe human protocol.
Evidence context: Preclinical / laboratory evidence
The biological rationale
IGF-1 LR3 is an engineered IGF-1 analogue. Its modifications reduce binding to some IGF-binding proteins, changing its availability in experimental systems.
It can activate the IGF-1 receptor, a growth-signalling receptor. That is different from stimulating the pituitary to release GH, and direct human evidence for LR3 itself is very limited.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
No validated human therapeutic or performance dose for IGF-1 LR3 has been established.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
LR3-specific research context
Preclinical · no established routine human regimenIGF-1 LR3 is not the licensed IGF-1 medicine mecasermin. Mecasermin dose instructions and animal exposure cannot validate an LR3 calendar programme. Any existing record stays manual; no growth-factor escalation is supplied.
Form and route: IGF-1 LR3 research analogue
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Growth-factor activity has important trade-offs
What the current evidence saysIGF signalling can affect glucose regulation and cell proliferation. The absence of a validated LR3 treatment programme makes product quality, dose-response and long-term safety major uncertainties.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
2 sourcesSources used on this profile
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
IGF-1 LR3 is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.